Phibro Animal Health Corp

Phibro Animal Health Corp(PAHC)の株式分析

$37.670

+1.367 (+3.63%)終値時点

Loading chart…
High
38.650
Open
36.360
VWAP
37.56
Vol
362.75K
Mkt Cap
696.66M
Low
36.360
Amount
13.63M
EV/EBITDA, TTM
8.69

Phibro Animal Health Corporation is a diversified developer, manufacturer and marketer of a range of animal health and mineral nutrition products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. The Company is also a manufacturer and marketer of performance products for use in the personal care, industrial chemical and chemical catalyst industries. Its segments include Animal Health, Mineral Nutrition and Performance Products. The Animal Health segment develops, manufactures and markets antibacterials which inhibit the growth of pathogenic bacteria that cause infections in animals. The Mineral Nutrition segment manufactures and markets formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.

www.pahc.com

AI analysis of Phibro Animal Health Corp (PAHC)

buy

Phibro Animal Health Corp (PAHC) is a good buy right now due to its strong recent financial performance and positive growth outlook. The current price is $37.67, and the company reported a 37% increase in adjusted net income for Q4 2026, reaching $35 million. Additionally, the forward P/E ratio is 13.83, indicating potential undervaluation compared to future earnings. However, the main risk is the analyst downgrade from Citi, which lowered the price target significantly to $44, citing regulatory headwinds.

Analyst Ratings (6)

+26.10% upside
Sell
1 Buy
2 Hold
3 Sell
Current: 37.67
安値
45.00
平均
47.50
高値
50.00

Citi

2026-05-14

目標株価

$44

Neutral

Citi

2026-05-13

目標株価

$44

Neutral

Citi

2026-04-15

目標株価

$62

Neutral

Morgan Stanley

2026-02-06

目標株価

$49

Equal Weight

JPMorgan

2025-11-07

目標株価

$50

Overweight

バリュエーション指標

The current forward P/E ratio for Phibro Animal Health Corp (PAHC) is 13.83, compared to its 5-year average forward P/E of 12.69.

Forward P/E

Fair
5Y Average P/E
12.69
Current P/E
13.83
割高
15.06
割安
10.33

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
8.83
Current EV/EBITDA
8.69
割高
10.12
割安
7.54

Forward P/S

Fair
5Y Average P/S
0.77
Current P/S
0.92
割高
1.00
割安
0.53

Whales holding PAHC

C

Castleknight Management LP

+ HoldingPAHC

-12.85%

3M Return

イベントタイムライン

2026-08-26 (ET)

20:00:00

Salesforce Shares Rise 12.8% After Earnings Boost

16:30:00

Sees FY27 Revenue of $1.55B to $1.6B

16:30:00

Phibro Animal Health Q4 Revenue $396.7M Beats Expectations

2026-05-06 (ET)

16:50:00

Raises FY26 Revenue Outlook to $1.46B-$1.5B

16:40:00

Phibro Animal Health Reports Q3 Revenue of $383.5M

ニュース

PAHC FAQ — answered by Alphio AI

Phibro Animal Health Corporation is a diversified developer, manufacturer and marketer of a range of animal health and mineral nutrition products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. The Company is also a manufacturer and marketer of performance products for use in the personal care, industrial chemical and chemical catalyst industries. Its segments include Animal Health, Mineral Nutrition and Performance Products. The Animal Health segment develops, manufactures and markets antibacterials which inhibit the growth of pathogenic bacteria that cause infections in animals. The Mineral Nutrition segment manufactures and markets formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Phibro Animal Health Corp (PAHC) is a good buy right now due to its strong recent financial performance and positive growth outlook. The current price is $37.67, and the company reported a 37% increase in adjusted net income for Q4 2026, reaching $35 million. Additionally, the forward P/E ratio is 13.83, indicating potential undervaluation compared to future earnings. However, the main risk is the analyst downgrade from Citi, which lowered the price target significantly to $44, citing regulatory headwinds.

6 analysts cover PAHC: 1 rate it Buy, 2 Hold and 3 Sell. The average price target is 47.50.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める